Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 143 for:    Venetoclax AND Leukemia

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04070768
Recruitment Status : Recruiting
First Posted : August 27, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborators:
Pfizer
AbbVie
Information provided by (Responsible Party):
Big Ten Cancer Research Consortium

Brief Summary:

This is a Phase Ib Study to determine the Maximum Tolerated Dose (MTD) of Venetoclax in combination with Gemtuzumab Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, subjects will receive once cycle of combination therapy. After one cycle of combination therapy, subjects showing response will continue on to one cycle of consolidation therapy with GO\Veneoclax. Subjects who respond to combination therapy will continue on maintenance Venetoclax until progression or unacceptable toxicity.

Dose-limiting toxicity, defined as an adverse event related (possible, probably, or definite) to Venetoclax and/or Gemtuzumab fulfilling one of the following criteria:

  • Hematologic toxicity: treatment-related grade 4 or worse bone marrow hypocellularity present at the end of cycle one (day 28); specifically grade 4 cytopenias (anemia, neutropenia and/or thrombocytopenia) with the bone marrow documented to be free of leukemic infiltration. Note: patients who enter the study with grade 3 or worse cytopenias will not be evaluable for hematologic dose-limiting toxicities.
  • Non-hematologic toxicity: any grade 3 or worse treatment-related toxicity (excluding grade 4 infections during cycle one).

The study will also evaluate the Overall Response Rate, Anti-leukemic activity, Relapse-free Survival (RFS), event-free survival (EFS) , and overall survival (OS). The study will evaluate quality of life using the European Organization for the Research and Treatment of Cancer 30 item questionnaire (EORTC QLQ-C30).


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Gemtuzumab Ozogamicin Drug: Venetoclax Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Actual Study Start Date : September 6, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2021


Arm Intervention/treatment
Experimental: Gemtuzumab Ozogamicin(GO) + Venetoclax
Gemtuzumab Ozogamicin(GO) + Venetoclax
Drug: Gemtuzumab Ozogamicin
Gemtuzumab Ozogamicin 3mg/m^2, Days 1,4,7
Other Name: GO

Drug: Venetoclax
Venetoclax, 100,200,400, or 600mg Daily Dose




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of Venetoclax when administered with GO [ Time Frame: 42 days ]

    Assess the maximum tolerated dose (MTD) of Venetoclax when administered with GO in patients with AML.

    • Dose-limiting toxicity, defined as an adverse event related (possible, probably, or definite) to Venetoclax and/or Gemtuzumab fulfilling one of the following criteria:

      • Hematologic toxicity: treatment-related grade 4 or worse bone marrow hypocellularity present at the end of cycle one (day 28); specifically grade 4 cytopenias (anemia, neutropenia and/or thrombocytopenia) with the bone marrow documented to be free of leukemic infiltration. Note: patients who enter the study with grade 3 or worse cytopenias will not be evaluable for hematologic dose-limiting toxicities.
      • Non-hematologic toxicity: any grade 3 or worse treatment-related toxicity (excluding grade 4 infections during cycle one.


Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: 7 months ]
    Overall response rate (CR/CRi), as defined by the revised IWG criteria

  2. Rate of Anti-leukemic activity [ Time Frame: 7 months ]
    Anti-leukemic activity (CR/Cri/PR), as defined by the revised IWG criteria

  3. Relapse-free survival [ Time Frame: 7 months ]
    patients achieving CR or CRi; measured from the date of achievement of a remission until the date of relapse or death from any cause; patients not known to have relapsed or died at last follow-up are censored on the date they were last examined

  4. Event-free Survival [ Time Frame: 7 months ]
    Event-free Survival will be measured from the date of entry to the date of treatment failure, disease relapse, or death from any cause; patients not known to have any of these events are censored on the date they were last examined

  5. overall survival [ Time Frame: 7 months ]
    Overall survival will be measured from the date of entry to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Ages 18 to 75 years at the time of consent.
  • ECOG Performance Status of 0-2 within 7 days prior to registration.
  • Patients must have AML, as defined,28 that is relapsed or refractory. Prior therapy including chemotherapy, immunotherapy, biological or targeted therapy (e.g. FMS-like tyrosine kinase-3 (FLT3) inhibitors, other kinase inhibitors, azacitidine, ATRA) is allowed.
  • CD33 expression by flow cytometry, assessed as CD33 expression in at least 20% of the leukemia blasts per local pathologist.29
  • Prior cancer treatment must be completed at least 21 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline.
  • Demonstrate adequate organ function as defined in the protocol.
  • Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months
  • Females of childbearing potential and males must be willing to use effective contraception during treatment and for at least 30 days after the last dose of Venetoclax. Females will be advised to use effective contraception for at least 6 months after the last dose of Gemtuzumab and males for at least 3 months after the last dose of Gemtuzumab.
  • As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

  • Patients with history of prior use of GO or Venetoclax
  • History of myeloproliferative neoplasm [MPN] including myelofibrosis, essential thrombocythemia, polycythemia vera, CML with or without BCR-ABL1 translocation, and AML with BCR-ABL1 translocation.
  • More than two lines of prior therapy.
  • WBC >25 × 109/L. Cytoreduction is required (hydroxyurea as per local standard of care).
  • Acute promyelocytic leukemia.
  • Unresolved ≥grade 2 clinically significant nonhematologic toxicities from prior anticancer therapy or unresolved disseminated intravascular coagulation ≥ grade 2 per CTCAE v5 criteria.
  • History of other malignancies within 1 year prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities), with curative intent.
  • Investigational drug within 4 weeks of study entry.
  • History of CHF requiring treatment, left ventricular ejection fraction ≤ 50%, cardiac insufficiency grade III or IV per New York Heart Association classification (NYHA), or chronic stable angina.
  • Patients who are HIV positive.
  • Known CNS involvement with AML.
  • Previous hematopoietic stem cell transplant within 2 months.
  • Previous history of veno-occlusive disease/sinusoidal obstruction syndrome.
  • Patients who are positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. Subjects with serologic evidence of prior vaccination to HBV [i.e., HBs Ag-, and anti-HBs+] may participate.
  • Active uncontrolled infection or severe systemic infection. Enrollment is possible after control of infection, at discretion of the treating physician.
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • Patients who have received strong and/or moderate CYP3A inducers or inhibitors within 7 days prior to the initiation of study treatment. (See Appendix III)
  • Patients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
  • Malabsorption syndrome or other condition that precludes enteral route of administration.
  • Psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up.
  • Unable or unwilling to undergo a screening bone marrow study.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04070768


Contacts
Layout table for location contacts
Contact: Robyn Lillie, RN/BSN 3176345842 ext 60 rlillie@hoosiercancer.org
Contact: Sean Quigley, MD 312-413-1300 seanq@uic.edu

Locations
Layout table for location information
United States, Illinois
Univeristy of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Roxana Toh    312-996-2088    rtoh@uic.edu   
Principal Investigator: John "Sean" Quigley, MD         
Sponsors and Collaborators
Big Ten Cancer Research Consortium
Pfizer
AbbVie
Investigators
Layout table for investigator information
Principal Investigator: Sean Quigley, MD University of Illinois at Chicago

Layout table for additonal information
Responsible Party: Big Ten Cancer Research Consortium
ClinicalTrials.gov Identifier: NCT04070768     History of Changes
Other Study ID Numbers: BTCRC-AML17-113
First Posted: August 27, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Big Ten Cancer Research Consortium:
relapsed
refractory
CD33+
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Venetoclax
Gemtuzumab
Antineoplastic Agents
Antineoplastic Agents, Immunological